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In the view of a clinician who has been providing methadone therapy since its inception 40
years ago, the status of the treatment today reflects the culmination of two trends:  an
increase in understanding, skills, and standards on the one hand, and a deterioration of
patients’ health on the other. A retreat of stigma, greater physician interest, and the evolu-
tion of standards are beginning to move the treatment toward the mainstream.
A
s methadone maintenance treatment enters its fifth decade, opioid treat-
ment programs (OTPs) are drawing on lessons learned from past successes
and failures to continuously improve the treatment modality. Today’s patients
span an age range wider than ever before, and present with a greater quantity and
severity of addictions and health problems. In the face of this, OTPs have access
to improved research and technology, and have also developed a greater under-
standing of the full dimensions of opioid addiction and recovery. We now know
that opioid addiction is a chronic disease, so we no longer think of methadone
as a short-term bridge to recovery, but instead consider it an intervention that
may be beneficial indefinitely.
Today’s OTPs must conform to regulations that are more rigorously enforced
than those of the past, but also more practical. While requiring treatment providers
to document and analyze their outcomes and correct shortcomings, the regula-
tions give clinicians latitude in planning treatment and prescribing methadone
dosages. This report describes the current methadone treatment population, sur-
veys the principles of contemporary use of the medication, reviews the history
and experience that have brought our understanding and skills to their current
high level, and identifies challenges and opportunities for improving the treat-
ment and treatment environment.
TODAY’S METHADONE PATIENTS
Today’s methadone patients differ from those of the past. The HIV and hepati-
tis C epidemics, the rise of polydrug abuse, and a widening age spread among
heroin abusers have multiplied the concerns and complexities of treatment. As
well, we now have a contingent of very experienced, long-term methadone patients
who can function as effective treatment allies to clinicians and their fellow patients 26 • SCIENCE & PRACTICE PERSPECTIVES—DECEMBER 2005
as well as forceful advocates for patients’ views and 
interests. 
Patients Are Sicker
Methadone treatment providers today work with a
patient population that has unprecedented levels of
drug exposure, addiction severity, and physical and
mental health comorbidity. While research and clin-
ical experience have equipped clinicians with better
understanding, skills, and interventions than ever
before, decades of steady deterioration in patients’
general health have contributed to a stasis or slight
worsening of overall methadone treatment outcomes.
Thirty years ago, the great majority of methadone
patients abused only heroin. In New York State today,
approximately 30 percent abuse other substances as
well, including alcohol, cocaine, methamphetamine,
benzodiazepines, and marijuana (New York State
Office of Alcoholism and Substance Abuse Services,
2005). Methadone does not reduce abuse of these
other drugs, which obviously can impede the behav-
ioral and social normalization that are the main goals
of methadone maintenance.
Hepatitis C is now the most prominent and wor-
risome co-occurring physical disease among methadone
patients. In New York City, the prevalence rate for
this infection has remained steady, at around 75 per-
cent, since detection by a diagnostic blood test first
became possible in the late 1990s. With passing time,
though, more and more patients are progressing to a
symptomatic disease stage, and the number requir-
ing hospitalization has risen dramatically. In our pro-
gram, about 600 of the 4,000 patients require a hos-
pital bed each year, with the great majority of these
related to hepatitis. Liver disease has replaced HIV
as the leading cause of death among our patients.
HIV infection currently affects some 20 percent
of patients in our program, down from twice that high
in 1992. Despite effective treatments that have greatly
reduced mortality from HIV, the impact of HIV or
hepatitis on patients’ morale and the need to coordi-
nate infectious disease medications with methadone
can substantially complicate recovery. For example,
rifampin (used to treat tuberculosis), AZT (for AIDS),
and interferon (for hepatitis C) all interact with
methadone to cause changed blood levels and side
effects that can, if not carefully monitored by clini-
cians, lead some patients to relapse.
Roughly 60 percent of our patients have treat-
able depression or anxiety intertwined with their sub-
stance use during the initial treatment phase. This
number is much higher today than in the 1970s, either
because more patients present with these disorders,
we have learned to more consistently identify them,
or both. One indication that mental health comor-
bidity may truly have expanded in the heroin-
abusing population is the trend toward increasing use
of other drugs along with heroin. In theory, this may
reflect an increase in the number of individuals attempt-
ing to control their anxiety symptoms with sedatives
and self-treat their depression with stimulants. With
chronic escalating use, self-medication with these
drugs backfires, ultimately exacerbating depressive
and anxiety disorders and increasing clinicians’ need
to monitor patients for suicidal behavior and other
severe mental health complications.
Patients Are Younger and Older
During the past several years, more young people aged
18 to 25 have come to OTPs for treatment. These
youths bring the cognitive and emotional dynamics of
adolescence and early adulthood to the clinic, as well
as a very high prevalence of multiple substance abuse. 
Programs also are treating patients who are older
than ever before. Some seniors have aged while in
methadone therapy, and others are presenting for the
first time in their 50s, 60s, and 70s. New York State
now has 10 patients over 80. Older patients pose a
unique set of clinical challenges related to the med-
ical issues of aging, such as diabetes, hypertension,
menopause, and reduced mobility.
Patients Are Better Informed
Methadone patients as well as providers have learned
much from their experiences over the past four decades.
Today’s patients, especially those older individuals
who have engaged in therapy continuously or repeat-
edly over many years, constitute a well-informed group
of consumers. In New York, they often know about
the various models for treating heroin addiction and
understand that if one program does not meet their
needs, they can try another.
Longer term methadone patients can provide
programs with valuable insights on how to meet their
clients’ needs and on reasonable goals and expecta-
tions. To take advantage, some programs have added
patients to their advisory boards and organized patient
advisory committees (PACs). In some cases, PACs
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and other patient liaisons have helped clinics respond
to patient and community concerns before they became
problematic. Many clinics seek input from their
patients via patient satisfaction surveys that ask: “What
do you think of the treatment you’re receiving? What
is working for you? What isn’t?” New York and other
states have ratified patients’ authority to bring their
experience to bear by mandating such surveys. 
Agencies such as the Joint Commission on Accredita-
tion of Healthcare Organizations (JCAHO) and the
Commission on Accreditation of Rehabilitation
Facilities (CARF) make collecting patient feedback
a requirement for OTP accreditation. PACs are another
way to meet this standard, which now is federally
mandated. 
Today’s patients are effective treatment allies as
well through activities that effectively extend the 
treatment network. Peer support groups, such as
Methadone Anonymous, give patients opportunities
to interact outside an OTP with others who have been
or are going through the treatment process. Another
group, The National Alliance of Methadone Advocates, 
has led the movement to protect patients’ rights and
ensure that their perspectives are heard by providers
and policymakers.
Patients also form “buddy groups” to support
each other during difficult phases of the treatment
process. For example, before a patient can begin inter-
feron/ribavirin treatment for hepatitis C, he or she
must first undergo several tests, including a liver
biopsy. The biopsy procedure can be intimidating,
and it is helpful to have a patient who has had the
procedure accompany the patient to the surgical cen-
ter and provide support and advocacy.
TREATMENT GOALS AND FEATURES
The defining characteristic of care in today’s OTPs,
distinguishing them from those in the past, is increased
tailoring of treatment to each patient’s individual
goals and needs. Four decades of clinical experience
and research have equipped OTP clinicians with
awareness, tools, and skills to adapt care plans to a
wide range of physical and mental health comor-
bidities, family and social circumstances, and recov-
ery expectations. 
Treatment Goals
The initial technical goals of methadone treatment
are to relieve the patient’s narcotic craving, sup-
press the abstinence syndrome, and block the euphoric
effects associated with heroin. The overall goal is to
improve the patient’s health and quality of life.
Intermediate objectives include improving patients’
access to and utilization of health care, teaching them
to reduce their risk for infectious diseases such as HIV
and hepatitis, and helping them build healthy rela-
tionships and reenter the workforce or school.
The cumulative experience with methadone has
led providers to reexamine one of the original assump-
tions regarding this therapy:  that all patients should
strive to be drug-free. In recent years, a gathering con-
sensus has endorsed methadone maintenance as a
chronic, potentially lifelong treatment. This view har-
monizes with recent emphasis on the chronic, episodic
nature of heroin addiction.
The public and policymakers are making this
conceptual adjustment more slowly, which can lead
to some tension over expectations. Many patients,
particularly in their first treatment episode, want to
taper their methadone dosage when their cravings
subside and they see themselves progressing in other
areas of their lives. Although some truly can abstain
from methadone and still have reasonable hope for
stable long-term recovery, overall, research has found
that up to 80 percent of patients who quit methadone
relapse to opioid abuse within 3 years (Ball and Ross,
1991; Joseph, Stancliff, and Langrod, 2000). In our
program, we teach that the measure of success is
not whether you take a medicine in the morning, but
whether you take care of yourself and your family, act
responsibly, and contribute to society. Even those who
can thrive without methadone are unlikely to do 
so unless they remain connected to some form of 
treatment.
Dose and Schedule
Methadone dosing is a prime area where the princi-
ple of individualized treatment has emerged in sharp
contrast to past practice. Clinicians today benefit
from developments that have greatly enhanced the
ability to identify and provide each patient with a
dosage that completely suppresses craving and heroin
abuse and produces minimal side effects.
First, we have learned that adequate dosage 
varies greatly. While some individuals do well on as
little as 20 mg/day, others require up to 10 or 15 times
as much or more. Differences in native metabolism
and in the effects of methadone’s interaction with28 • SCIENCE & PRACTICE PERSPECTIVES—DECEMBER 2005
other concurrent medications underlie this wide range
(see “Alcohol and Medication Interactions With
Buprenorphine and Methadone” in Science & Practice
Perspectives Vol. 2, No. 2, pp. 10-11). The most fre-
quently encountered interactions occur in patients
receiving medications for HIV—some of which speed
and some of which slow methadone metabolism—
and for hepatitis C. Patients taking interferon for hep-
atitis C may need upward adjustment in their methadone
dosage to counteract a toxic effect of the antiviral med-
ication that mimics opioid withdrawal.
The patient’s response to methadone—whether
he or she continues to crave or abuse heroin, or feels
excessively drowsy—is the essential indicator of whether
the prescribed dosage is too little or too much. To
determine this, we talk with the patient to find out if
he or she has tried taking opioids while on methadone,
and, if so, why and what kind of opioid effect was felt.
We ask what time of day drug-taking occurs, which
is oftentimes when methadone blood levels are bot-
toming out.
The move to fully individualized dosing, like the
acceptance of indefinitely long methadone therapy,
has not yet happened everywhere. A few states still
place ceilings on prescription amounts. A recent study
of about 30 OTPs over a 10-year period found that
programs where doctors freely determined methadone
dosage were more likely to give adequate amounts
than programs where public policy limited the options
(D’Aunno, Folz-Murphy, and Lin, 1999).
Attention to Co-Occurring Conditions
Today’s OTPs recognize the adverse impact of co-
occurring addictions and comorbid illnesses on their
patients’ progress in treatment, but, in general, we
have yet to evolve broadly applicable standards for
responding. Given their very long-term trend toward
ever-higher prevalence, these problems are prime can-
didates for research attention. Unfortunately, even
where research has proven one or another approach
to be effective, funding limitations prohibit many
programs from implementing the best practices. 
Co-Occurring Addictions
Some OTPs insist that patients attend groups and
honestly address their co-occurring addictions in treat-
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ment or else face termination; others do not place
limits on treatment and continue to try to motivate
patients to stop using nonopioid drugs. Studies have
shown that medications can help patients in methadone
treatment reduce alcohol and cocaine abuse (aman-
tadine, serotonin reuptake inhibitors). In one study,
investigators used a breathalyzer test to determine
which patients were the worst abusers of alcohol, then
asked these patients to either begin taking Antabuse
or transfer to another clinic. All agreed to take Antabuse
and, for the length of the 90-day study, none drank
alcohol (Bickel et al., 1988).
Whatever a program’s policies may be, clinicians
need to consider each patient’s overall behavior when
deciding how to react to his or her abuse of other
drugs. A patient who is honest about drug abuse and
wants to stop should not be treated in the same man-
ner as one who refuses to attend group meetings or
follow through with treatment plans or activities. 
The former is struggling with craving and making an
effort; the latter does not appear motivated to accept
treatment.
Co-Occurring Medical Illnesses
Methadone programs that offer comprehensive men-
tal and physical health services obtain significantly
better outcomes for their patients (National Institute
on Drug Abuse, 1999). One particularly successful
model is “one-stop shopping,” where patients receive
all services at the same site (Barnett and Hui, 2000).
While these principles are well accepted across the
field, many smaller programs lack the resources to
put them into practice. These programs instead refer
patients to other facilities, encourage them to follow
up, and hope they do. The hopeful element in today’s
picture, discussed below, is that mainstream medical
practitioners increasingly are willing to treat drug-
abusing patients.
Treatment Delivery Systems
Today’s OTPs have begun to evolve past the original,
rigid treatment delivery system that requires every
patient to report to a clinic for each day’s methadone
dose. In New York and some other locations, clinics
are implementing flexible, tiered systems that respond
to patients’ personal growth and changing circum-
stances as they advance in recovery.
Medical maintenance, a promising new arrange-
ment, allows individuals who have passed the initial
phases of therapy to obtain treatment in a physician’s
office. At New York Hospital/Cornell Medical Center
in New York City, for example, the patient sees a doc-
tor once a month, leaves a specimen for drug testing,
and gets a methadone prescription to fill at a local
pharmacy. He or she does not have to choose between
tapering and permanent clinic attendance, with its
potentially demoralizing exposure to the milieu of
recent heroin abuse. The arrangement recognizes that
these individuals have achieved significant control
over their illness, helps them establish normal 
physician-patient relationships, and enables them to
schedule treatment that doesn’t conflict with jobs
or other social obligations. As well, our office-based
opioid treatment frees up clinic beds for new patients
who require more structured services.
Another new model, the treatment phase approach,
divides treatment into highly structured stages (Hoffman
and Moolchan, 1994). All patients participate in the
first three:  intensive stabilization, commitment, and
rehabilitation. Patients then choose, with the help of
their doctor, between two tracks: medical mainte-
nance or tapering. The final phase is reinforcement.
OTPs using the treatment phase model frontload their
services to the people entering treatment, who have
the most need, involving them in good health care,
educating them about HIV and hepatitis C, and intro-
ducing them to outside resources that will provide
the medical care and social services they need. The
clinic staff works with patients to formulate treat-
ment plans that address patients’ problems in order
of urgency, such as criminal justice, mental illness,
housing, employment, and education. As the first set
of problems ease, the staff implements new services
for the next most serious until, eventually, the cumu-
lative improvement eliminates the need for most 
services.
A MAINSTREAM MEDICAL TREATMENT
Originally greeted with skepticism and suspicion,
methadone has survived to become an established
treatment for heroin abuse. Although negative per-
ceptions and stigma still persist in an attenuated
form—and everyone looks forward to the day when
OTPs can produce long-term recovery more quickly
and consistently—by and large, heroin abusers, com-
munities, policymakers, and researchers now accept
that the therapy’s proven efficacy makes it worth try-
ing, supporting, and refining. In this new climate
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of increased tolerance, methadone therapy has entered
a transition from the margin toward the mainstream
of medicine.
The Partial Retreat of Stigma
The disclosure through scientific research that addic-
tion is a chronic disease, bolstered by examples of suc-
cessful recovery, has tempered the stigmatizing of
methadone patients and their treatment. The shift
toward a health-based rather than moral concept of
addiction, while not yet complete, has progressed
remarkably swiftly, when we consider that it was only
in 1997 that the National Institutes of Health first
urged this view on the medical establishment (National
Institutes of Health, 1997).
Despite this greater tolerance of opioid replace-
ment treatment, methadone diversion and loitering
near clinics remain potent sources of negative atti-
tudes toward OTPs. Neighbors tend to notice those
individuals who hang around, get arrested, and require
ambulance transport to the emergency room, rather
than the majority who simply walk in and out of the
clinic and get on with their lives. Taxpayers are loath
to see their money going to provide addicted indi-
viduals with opioids to sell to other drug-abusing 
individuals. As well, although an investigation deter-
mined that diversion from OTPs has not been the
primary cause of a recent increase in methadone-
related death rates (Center for Substance Abuse
Treatment, 2004), communities fear the medication’s
potential lethality. 
Strengthening communication between OTPs
and their communities and stakeholders has proved
an effective strategy for allaying these legitimate but
exaggerated concerns. Many programs now attend
planning board, precinct council, and other meetings
where they can hear and respond to community wor-
ries or complaints. As OTPs have become more inte-
grated into their communities over the decades, we
have found natural allies in churches, synagogues,
mosques, and even police departments and child wel-
fare agencies. All share the mission of assisting the
underserved, and all seek to strengthen messages of
sense and tolerance.
Some regulatory authorities now provide their
own impetus for OTPs to take active steps to improve
the public’s perceptions. New York State, for exam-
ple, requires programs to solicit and address com-
munity concerns and criticisms. Center for Substance
Abuse Treatment (CSAT) and accreditation regula-
tions require programs to implement plans to con-
trol methadone dose diversion. The programs must
know where their patients go after they leave the clinic
and also assess their patients for potential diversion.
Physician Engagement
Physician investment in methadone therapy stands
at its highest level ever. In the early days, some pro-
grams were lucky if they could find a part-time or
retired physician to come in and oversee the methadone
prescribing. Now, we turn away highly trained 
doctors.
Many doctors first became interested in methadone
in the late 1980s, when studies showed that patients
in treatment had lower rates of HIV infection than
active heroin injectors (Blix and Gronbladh, 1988;
Kreek et al., 1990; Metzger et al., 1993). These
doctors initially approached methadone therapy pri-
marily as a way to slow the AIDS epidemic through
testing, educating, and counseling intravenous
drug abusers. Subsequently, through involvement
with the patients and programs, many have become
fully engaged in the issues of addiction itself.
Establishing Standards
In the improved treatment climate, no longer con-
strained to constantly justify their existence, metha-
done treatment systems have begun to move toward
the medical mainstream. We are accomplishing this
with the same tools other medical specialties have
used to establish and sustain the quality of their 
services and their prestige:  setting standards for staff
qualification and program accreditation.
In New York State now, 25 percent of treatment
staff in every clinic must be certified alcoholism
and substance abuse counselors. In 2001, CSAT intro-
duced a nationwide accreditation system whereby
programs must demonstrate to a Federal accredit-
ing agency (e.g., CARF or JCAHO) that they meet
standards on measures such as lengths of stay, the
number of patients using opioids or other drugs while
in treatment, the number of patients able to find
employment and stay employed, and so on. By select-
ing a set of standardized performance measures, the
accreditation system enables the field to collectively
accomplish what many OTPs have always tried to do
individually: by collecting and analyzing information
on patients’ outcomes, identify which forms of treat-
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ment are most successful, learn from past mistakes,
and consistently improve success rates.
As the new system evolves and programs seek to
obtain accreditation, allowance must be made for the
different challenges faced by OTPs working in dif-
ferent environments. Just as we do not measure suc-
cess the same way for a homeless patient with a 20-
year history of incarcerations and a young person in
a first treatment episode, we cannot expect programs
serving divergent patient populations under con-
trasting circumstances to meet the same criteria for
outcomes.
WISH LIST
As OTPs continue to progress toward outcome-based
treatment standards and integration with mainstream
medicine, we can anticipate growing success in help-
ing our patients meet the many challenges of their
addictions and their lives. The continuation of these
trends, together with further increases in the public
and professional acceptance of methadone, must be
at the top of everyone’s wish list for methadone treat-
ment. Beyond that, I believe the following develop-
ments could advance the cause dramatically:
• A medication for cocaine addiction.
• Upgrading of the physical facilities and locations
of clinics. The current placement of most facili-
ties in cramped spaces in shabby buildings in mar-
ginal neighborhoods can make the treatment expe-
rience awkward and intimidating. Ideally, clinics
should have the physical space to allow staff to give
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private, confidential treatment, while also having
larger areas for group meetings.
• More effective standardized assessment tools for
patients with serious comorbidities, such as poly-
substance abuse and mental illness. The Addiction
Severity Index and other existing tools are useful,
but we need a set of standardized tools that are specif-
ically for methadone treatment, and that all our cli-
nicians, with their array of educational backgrounds,
can use to guide the treatment planning process.
• A concerted effort to educate the public on the ben-
efits of methadone treatment. A Federal effort to
reduce the stigma associated with methadone treat-
ment could help educate people on the nature of
drug addictions and on why methadone is so impor-
tant, not only to those who abuse drugs, but to soci-
ety as a whole. 
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Warren Bickel: The paper provides a good general
overview of the changes that have taken place in
methadone treatment over the years. Its basic mes-
sage is appropriate: Methadone treatment is effective
and is being more widely accepted.
George Bigelow: Yes. I do think, though, that the
paper overstates the extent to which methadone treat-
ment has entered the medical mainstream. Mr. Marion’s
program is in New York City, where methadone has
a longer history and more public support than many
or most other places.
Bickel:  I agree. The State of Vermont, for example,
has one methadone clinic, which has a waiting list of
over a hundred people. Here in Arkansas, we only
have two methadone programs in the Little Rock area.
This article serves as a reminder that methadone is
effective, and therefore we need to do what we can to
continue to bolster its acceptance by both the public
and the medical and rehabilitation communities.
Kyle Kampman: Many programs still have difficulty
recruiting for medical staff positions. And while there
may be less stigma today, plenty still exists—not only
against methadone and methadone patients, but also
extending to physicians and psychiatrists who work
with them.
Bigelow: Overall, nationwide, I don’t think there is
any other medication that is so effective and yet so
hard to get as methadone.
Older patients, younger patients
Bigelow: Mr. Marion describes the aging of the
methadone population, which of course is testimony
to the effectiveness of the treatment. Methadone has
significantly extended the life expectancy of opiate
abusers. One corollary has been the creation of a group
of patients with more concurrent medical disorders
of the type that all aging populations have, such as
hypertension and diabetes. Our group recently pub-
lished a study on this issue and the challenges it will
create for treatment providers [Lofwall et al., 2005].
Kampman: Partly because of the medical problems
related to aging, and partly due to opioid abusers’
high propensity for trauma, we see a lot of patients
with pain. Many come to us through referrals from
pain management specialists who are apprehensive
about treating opiate-dependent patients. Chronic
pain is a difficult problem to manage anywhere,
and perhaps more so in a methadone clinic. We would
greatly benefit from new research in this area.
Bickel: The larger number of new, young opioid-
dependent patients speaks to the need to have mul-
tiple treatment options. It is not helpful to place a
person who has recently become involved with pre-
scription drugs in treatment with patients having
extensive histories of drug dependence. We need to
expand the range of options, so that different types
of patients can receive appropriate treatments.
Bigelow: One respect in which our experience seems
to differ from Mr. Marion’s is the 60 percent figure
he cites for treatable depression among methadone
patients. That is considerably higher than we see in
Baltimore. I can’t think of a reason why there should
be such a difference, except perhaps that Mr. Marion’s
figure reflects assessments made at intake. We find
that many of our patients are depressed because of
the difficulties of the opioid-abusing lifestyle, but
their mood recovers once they are normalized on
methadone.
Treatment models and settings
Bickel: I think it is very important to keep in mind
that methadone is only one part of the larger treat-
ment picture. The research agenda should include
how we can best utilize both methadone and buprenor-
phine to provide a true continuum of care where every
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patient receives treatment in an appropriate modal-
ity. The interesting questions in methadone research
right now aren’t about its efficacy as a pharmacolog-
ical agent—that was established long ago. They are
about the different ways of delivering methadone and
how to best incorporate social and behavioral coun-
seling in the treatment.
Bigelow: For example, Mr. Marion talks about
methadone medical maintenance, where stabilized
patients can transfer their visits from the clinic to a
physician’s office. I think we should keep striving to
develop models like that, so that patients and physi-
cians can have maximum flexibility in the choice of
treatments as well as treatment settings.
Bickel: Tom McLellan’s group [McLellan et al., 1993]
examined the importance of counseling, medical care,
and psychosocial services with respect to the outcomes
of methadone patients. They concluded you could
make methadone treatment outcomes look either hor-
rible or successful based on the quantity and quality
of accompanying psychosocial treatments.
Bigelow: I agree. The psychosocial and behavioral
treatments that accompany the pharmacotherapies
are critically important, if only because they can be
applied to the full range of substance abuse disorders.
The drawback of a medication such as methadone is
that it is pharmacologically specific—it will only treat
opioid addiction—whereas today’s patients tend to
be polydrug abusers. 
Bickel: Our group has been looking at different ways
of delivering psychotherapies. Recently we completed
a trial where we compared the results of computer-
delivered cognitive-behavioral treatment with the
same treatment delivered by a therapist, along with a
control treatment. So far, the results appear to show
that the computer- and therapist-delivered treatments
were better than the control, but not significantly dif-
ferent from each other, suggesting that we may be able
to use computer technology to expand access to
psychotherapies.
Bigelow: The NIDA Clinical Trials Network has con-
ducted a study of the effectiveness of motivational
incentives to reduce stimulant abuse in methadone
clinics. Though the data are still in review, the incen-
tives appear to have had a positive impact, as meas-
ured by the frequency of stimulant-negative urine
samples during treatment. Another area where I think
significant research is needed is the development of
longer acting methadone dosage forms, which would
make the medication more convenient while also
reducing the risk of overdose and diversion.
Unfortunately, I don’t think anyone is looking into
this. &
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